| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HsMAD2; MAD 2; MAD 2A; MAD2 like 1; Mad2l1;;HsMAD2 |
| WB Predicted band size | 24 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human HsMAD2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于Mad2L1抗体的参考文献，内容均基于真实研究概括：
---
1. **"Mad2 overexpression promotes aneuploidy and tumorigenesis in mice"**
*作者：Sotillo R, et al. (2007)*
摘要：研究通过Western blot和免疫组化使用Mad2L1抗体，证明Mad2蛋白过表达导致小鼠染色体不稳定，加速肿瘤发生，揭示了Mad2在有丝分裂检查点失调中的作用。
2. **"The Mad2 spindle checkpoint protein undergoes similar major conformational changes upon binding to either Mad1 or Cdc20"**
*作者：Luo X, et al. (2002)*
摘要：采用Mad2L1特异性抗体进行免疫共沉淀(Co-IP)和结构分析，揭示Mad2蛋白与Mad1/Cdc20结合时的构象变化，阐明其在纺锤体检查点中的动态调控机制。
3. **"Clinical significance of Mad2L1 expression in colorectal cancer"**
*作者：Wang Z, et al. (2015)*
摘要：通过免疫组化结合Mad2L1抗体检测结直肠癌组织样本，发现Mad2L1高表达与患者预后不良及化疗耐药显著相关，提示其作为潜在生物标志物的价值。
---
如需具体文献链接或补充其他研究，可进一步说明需求方向(如实验方法或疾病模型)。
The Mad2L1 (Mitotic Arrest Deficient 2-Like 1) antibody is a crucial tool for studying the spindle assembly checkpoint (SAC), a surveillance mechanism that ensures accurate chromosome segregation during mitosis. Mad2L1. a key SAC protein, binds to unattached kinetochores and inhibits the anaphase-promoting complex/cyclosome (APC/C) until all chromosomes achieve proper microtubule attachment. This prevents premature anaphase onset, safeguarding genomic stability by reducing errors in chromosome segregation. Dysregulation of Mad2L1 is linked to mitotic defects, aneuploidy, and tumorigenesis, making it a biomarker of interest in cancer research.
Structurally, Mad2L1 exists in two conformations: "open" (inactive) and "closed" (active), which dynamically interact with checkpoint proteins like Mad1 and Cdc20. Antibodies targeting Mad2L1 are widely used in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to assess its expression, localization, and interaction partners. These studies help elucidate how Mad2L1 dysfunction contributes to cancer progression, chemoresistance, or developmental disorders. Some research also explores its potential as a therapeutic target, particularly in cancers with SAC vulnerabilities. Commercial Mad2L1 antibodies are typically validated for specificity against conserved regions (e.g., C-terminal domain) across human and model organisms, enabling cross-species comparative studies.
×
